Acrivon Q2 net loss $21.0M, cash $147.6M; advances ACR-368 and ACR-2316 trials

Acrivon Therapeutics, Inc.

Net loss of $21.0M for Q2 2025, up from $18.8M in Q2 2024; R&D spend $16.2M.
Cash, equivalents and investments of $147.6M as of June 30, 2025; expected runway into Q2 2027.
Initiated Phase 2b third arm for ACR-368 with ultra low-dose gemcitabine in biomarker-unselected endometrial cancer.
ACR-2316 Phase 1 dose escalation shows initial clinical activity, including confirmed partial response in endometrial cancer.
Anticipated H2 2025 milestones: update on registrational ACR-368 trial and initial Phase 1 data for ACR-2316.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.